Nemolizumab
- CAS No.
- 1476039-58-3
- Chemical Name:
- Nemolizumab
- Synonyms
- CIM331;Nemolizumab;Nemolizumab (anti-IL-31Ra);Research Grade Nemolizumab;Research Grade Nemolizumab(DHJ26601)
- CBNumber:
- CB68080930
- Molecular Formula:
- Molecular Weight:
- 0
- MDL Number:
- MOL File:
- Mol file
- MSDS File:
- SDS
| storage temp. | Store at -20°C |
|---|---|
| form | Liquid |
| color | Colorless to light yellow |
| FDA UNII | GN465U8B72 |
Nemolizumab price
| Manufacturer | Product number | Product description | CAS number | Packaging | Price | Updated | Buy |
|---|---|---|---|---|---|---|---|
| ChemScene | CS-0612563 | Nemolizumab 99.70% | 1476039-58-3 | 1mg | $238 | 2026-06-04 | Buy |
| ChemScene | CS-0612563 | Nemolizumab 99.70% | 1476039-58-3 | 5mg | $563 | 2026-06-04 | Buy |
| ChemScene | CS-0612563 | Nemolizumab 99.70% | 1476039-58-3 | 10mg | $921 | 2026-06-04 | Buy |
| aablocks | AA029IZ0 | Nemolizumab | 1476039-58-3 | 1mg | $135 | 2026-06-02 | Buy |
| aablocks | AA029IZ0 | Nemolizumab | 1476039-58-3 | 5mg | $295 | 2026-06-02 | Buy |
Nemolizumab Chemical Properties,Uses,Production
Uses
Nemolizumab (CIM331) is a humanized monoclonal antibody that targets the human interleukin-31 receptor a, preventing interleukin-31 (IL-31) from binding to its receptor and the subsequent signaling. Nemolizumab can help reduce itching and sleep disturbances, and it is being studied for atopic dermatitis (AD)[1][2].
in vivo
Nemolizumab (40-100 μg/kg, i.v., acute administration) blocks IL-31-induced scratching in cynomolgus monkeys[3].
Nemolizumab (1 mg/kg, s.c., acute administration) exerts a mean plasma concentration of 1490 ng/mL at Day 56 in 5 of 6 experiment cynomolgus monkeys and suppresses the scratching behaviour from shortly after administration until Day 56[3].
References
[1] Nakahara T, et, al. Nemolizumab and Atopic Dermatitis: the Interaction Between Interleukin-31 and Interleukin-31 Receptor as a Potential Therapeutic Target for Pruritus in Patients With Atopic Dermatitis. 2018;5:405–14.
[2] O Nemoto, et al. The first trial of CIM331, a humanized antihuman interleukin-31 receptor A antibody, in healthy volunteers and patients with atopic dermatitis to evaluate safety, tolerability and pharmacokinetics of a single dose in a randomized, double-blind, placebo-controlled study. Br J Dermatol. 2016 Feb;174(2):296-304. DOI:10.1111/bjd.14207
[3] Oyama S, et al. Cynomolgus monkey model of interleukin-31-induced scratching depicts blockade of human interleukin-31 receptor A by a humanized monoclonal antibody. Exp Dermatol. 2018 Jan;27(1):14-21. DOI:10.1111/exd.13236
Nemolizumab Preparation Products And Raw materials
Raw materials
Preparation Products
Nemolizumab Suppliers
| Supplier | Tel | Country | ProdList | Advantage | |
|---|---|---|---|---|---|
| Biolab Reagents | 027-65279366 18108604356 | products@biolabreagent.com | China | 9864 | 58 |
| BOC Sciences | 1-631-485-4226; 16314854226 | info@bocsci.com | United States | 9920 | 65 |
| Shanghai YuanYe Biotechnology Co., Ltd. | 15026964105 | 2881489226@qq.com | China | 89667 | 60 |
| ShangHai Biochempartner Co.,Ltd | 177-54423994 17754423994 | 2853530910@QQ.com | China | 8000 | 62 |
| TargetMol Chemicals Inc. | +1-781-999-5354; +1-00000000000 | marketing@targetmol.com | United States | 32431 | 58 |
| Guangzhou Hongyuan Chemical Co.,Ltd | 15817493340 | 981810490@qq.com | China | 1577 | 58 |
| Wuhan Chemstan Biotechnology Co., Ltd. | 027-65317797 15926423062 | 422450190@qq.com | China | 10305 | 58 |
| Beijing Jin Ming Biotechnology Co., Ltd. | 010-60605840 | psaitong@jm-bio.com | China | 27626 | 58 |
| TargetMol Chemicals Inc. | 4008200310 15002144251 | marketing@tsbiochem.com | China | 24951 | 58 |
| Wuhan Jingkangen Biomedical Technology Co., Ltd | 13720134139 086-15871494362 13720134139 | orders@jknbiochem.com | China | 7283 | 58 |
View Lastest Price from Nemolizumab manufacturers
| Image | Update time | Product | Price | Min. Order | Purity | Supply Ability | Manufacturer | |
|---|---|---|---|---|---|---|---|---|
 |
2026-07-27 | Nemolizumab
1476039-58-3
|
$143.00-562.00 | 100% (SEC-HPLC) | 10g | TargetMol Chemicals Inc. |
-
- Nemolizumab
1476039-58-3
- $143.00-562.00
- 100% (SEC-HPLC)
- TargetMol Chemicals Inc.
